Usando inhibidores de PARP en el tratamiento de las pacientes con cáncer de ovario: Cómo, Cuando, A quién y Por qué

Objective response rate (ORR)

in 4th and 5th line HRD patients

who are considered platinum sensitive to their

last platinum therapy was

29%

(95% CI 16–44, P=0.0003, n=45)

An “expanded primary” population was created to include 4

line or later, HRD

patients, sensitive to last platinum (n=51)

PARPi–exposed patients are not included

QUADRA Study:

1º End-Point: ORR